Filter by
Date
Cancer type
Cancer stage
Biomarker
Method of analysis
Selected categories
June 2025
Comparative Molecular Analysis of CTCs and ctDNA Detection using ANGLE’s Parsortix® System
ANGLE Europe Ltd, Guildford, UK, published at EACR Annual Meeting 2025
June 2025
Combined microfluidic isolation and immunofluorescence staining of circulating tumour cells for the assessment of Androgen Receptor expression in metastatic prostate cancer blood samples.
ANGLE Europe Limited, Guildford, UK, published at EACR Annual Meeting 2025
April, 2025
Analytical validation of ANGLE’s combined IF and FISH assay for assessment of HER2 in circulating tumor cells
ANGLE Europe Limited, Guildford, UK, published at AACR Annual Meeting 2025
January 2025
DDRi Summit 2025: Monitoring of DNA Damage Response Biomarkers using Circulating Tumour Cells captured with ANGLE’s Parsortix® instrument from Ovarian, Prostate, and Breast cancer patients
ANGLE Europe Limited, Guildford, UK, published at the 8th Annual DDR Inhibitors Summit 2025
December 2024
SABCS: A novel, semi-automated Pipeline for HER2 Quantification on CTCs in breast cancer patients. Is cytopathology of peripheral blood a new diagnostic option?
AACR LBx 24 – Development of a scoring system to classify HER2 protein expression in Circulating Tumour Cells through immunofluorescence following isolation using Parsortix® instruments
ANGLE Europe Limited, Guildford, UK, Published at the AACR LBx Conference 2024
1 23 ... 11